{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-085543","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2024-10-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.341079+00:00","generated_at":"2026-05-30T21:03:59.592418+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oruka Therapeutics amends CEO & SVP employment agreements, revising severance terms","bullets":["CEO Klein: outside CIC, severance = 12 months base salary + 30% time-based equity vesting. Within CIC, 1.5x base+bonus + full equity acceleration.","SVP Agarwal: outside CIC, 9 months base salary. Within CIC, 0.75x base+bonus + full equity acceleration and 9 months COBRA.","Agreements also provide full time-based equity acceleration upon death/disability for Klein.","Base salary ($600K for CEO) and target bonus (50% of base) remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-085543","json":"https://secwatch.observer/filing/0001213900-24-085543.json","markdown":"https://secwatch.observer/filing/0001213900-24-085543.md","text":"https://secwatch.observer/filing/0001213900-24-085543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390024085543/0001213900-24-085543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea0216746-8k_oruka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T21:03:59.592418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}